循环CD4+ T细胞腺苷代谢特征可预测类风湿关节炎缓解
研究纳入68例起始甲氨蝶呤治疗的早期类风湿关节炎初治患者,分析循环CD4+ T细胞中腺苷代谢相关靶点的表达。基线CD4+CD25高表达调节性T细胞上CD39表达更高及AMPD1、ADORA2b、ADORA3上调与6个月DAS28-CRP缓解相关,联合指标预测早期缓解的曲线下面积优于基线DAS28-CRP。
要点
- 基线CD4+CD25高表达调节性T细胞CD39表达在缓解者更高(1264 vs 847,p=0.007)。
- AMPD1(p<0.001)、ADORA2b(p=0.039)、ADORA3(p=0.047)在缓解者基线CD4+ T细胞中上调。
- 联合指标预测6个月缓解的曲线下面积0.92 vs 基线DAS28-CRP 0.67(p=0.001)。
核心结论
- 腺苷信号参与类风湿关节炎患者经甲氨蝶呤实现早期缓解,腺苷活性生物标志物可能有助于早期疾病治疗分层。
研究设计与样本
- 从68例起始甲氨蝶呤治疗的早期类风湿关节炎初治患者外周血中分离纯化CD4+ T细胞,采用流式细胞术和转录分析探索推定的甲氨蝶呤代谢与作用机制靶点表达。
- 通过逻辑回归(临床与流式细胞术数据)和线性建模(基因表达数据)确定DAS28-CRP缓解(6个月时<2.4)的显著预测因素。
主要发现
- 基线低DAS28-CRP与6个月时缓解相关(p=0.02)。
- 达到缓解者基线CD4+CD25高表达调节性T细胞上CD39表达更高(等效荧光分子数1264 vs 847;p=0.007)。
- 达到缓解者基线CD4+ T细胞中其他腺苷信号元件亦上调:AMPD1(p<0.001)、ADORA2b(p=0.039)和ADORA3(p=0.047)。
- 将这些变量组合为单一预测指标后,其预测早期缓解的表现优于基线DAS28-CRP(曲线下面积0.92 vs 0.67,p=0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Long-term outcomes in rheumatoid arthritis (RA) depend on early and effective disease control. Methotrexate (MTX) remains the first-line disease modifying therapy, however there are no biomarkers with which to identify those most likely to achieve remission. To address this unmet need we explored metabolic pathways involved in MTX mechanism of action within circulating CD4+T cells in a cohort of treatment naive patients with early RA. METHODS: Purified CD4+T cells were isolated from peripheral blood of 68 patients with early RA commencing MTX. The expression of a range of putative MTX metabolism and mechanism of action targets were explored by flow-cytometry and transcriptional analysis. From these data significant predictors of Disease Activity Score 28-C reactive protein (DAS28-CRP) remission (<2.4 at 6 months) were determined by logistic regression (clinical; flow-cytometry data) and linear modelling (gene expression data). RESULTS: Low baseline DAS28-CRP was associated with remission at 6 months (p=0.02). Expression of the ectonucleotidase CD39, involved in ATP-ADP conversion during adenosine synthesis, was higher on CD4+CD25 High regulatory T cells at baseline in those achieving remission (molecules of equivalent fluorescence 1264 vs 847; p=0.007). Expression of other adenosine signalling elements in CD4+T cells were also upregulated at baseline in patients achieving remission: AMPD1 (p<0.001), ADORA2b (p=0.039) and ADORA3 (p=0.047). When combined into a single predictive metric, a combination of these variables outperformed baseline DAS28-CRP in prediction of early remission (area under the curve 0.92 vs 0.67, p=0.001) CONCLUSIONS: Adenosine signalling is important in the achievement of early remission with MTX in RA and biomarkers of adenosine activity may hold utility for the stratification of therapy in early disease.
引用
- Brown PM, Anderson AE, Naamane N, et al. Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis. RMD Open. 2024. PMID: 38367982. doi:10.1136/rmdopen-2023-003858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。